GLYCEMIC CONTROL IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS ON PREMIXED INSULIN REGIMEN TO BASAL-BOLUS INSULIN

Abstract

Background: Insulin therapy forms the golden management strategy in subjects with diabetes mellitus in most of the subjects 
with T2D (type 2 diabetes mellitus) owing to it having a progressive and chronic nature.  
Aim: In an Indian setting, the current study sought to evaluate the side effects and glycemic control of individuals with type 
2 diabetes mellitus on a premixed insulin regimen against basal-bolus insulin.  
Methods: 120 participants with Type 2 diabetes mellitus who had had the disease for more than seven years were evaluated 
for this study. They were split into two groups of 60 at random, with Group I receiving BB management and Group II receiving 
an OM insulin regimen. At 4 and 12 weeks, changes in glycemic parameters as well as instances of hypoglycemia were 
evaluated. 
Results: FPG (fasting plasma glucose) decreased significantly with PM insulin from baseline at 4 weeks (p=0.01), but only 
at 12 weeks (p<0.001) did BB insulin show a meaningful drop.  At 4 and 12 weeks, the PM groups showed a greater decrease 
in FPG than the BB group (p=0.03 and 0.02 respectively). There was a substantial decrease in post-prandial plasma glucose 
from baseline to 4 weeks (p=0.03) and at 8 weeks (p<0.0001) for both. At 4 weeks, there was no intergroup difference 
(p=0.14). At 12 weeks, nevertheless, it was significant for the PM group (p=0.008).  
Conclusion, both the BB and PM insulin regimens significantly enhance glycemic control without putting their users at risk 
for severe hypoglycemia episodes. Therefore, patient-related factors like adherence and eating patterns, as well as insulin
related factors like complexity and posology, should influence the choice of insulin.